Real-world effectiveness and safety of avelumab first-line maintenance (1LM) treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Second interim analysis of the AVENUE study

Category Primary study
Conference2025 ASCO Genitourinary Cancers Symposium
Year 2025
This article has no abstract
Epistemonikos ID: 73bf252a8b898b9ce94fdf61b9ede7d50e18b1ca
First added on: Jan 22, 2026